<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04367935</url>
  </required_header>
  <id_info>
    <org_study_id>PHCL 289</org_study_id>
    <nct_id>NCT04367935</nct_id>
  </id_info>
  <brief_title>Effect of Pentoxifylline on Endothelial Dysfunction in Patients With Acute Coronary Syndrome</brief_title>
  <official_title>Effect of Pentoxifylline on Endothelial Dysfunction in Patients With Acute Coronary Syndrome: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the effect of pentoxifylline administration on the status of
      endothelial function and oxidative stress biomarkers in patients with Acute Coronary Syndrome
      (ACS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be carried out at Ain Shams University Hospitals. Patients with ACS who meet
      the eligibility criteria and consent to participate in the study will be randomly allocated
      to either the intervention group or the control group.

      All participants will receive the standard pharmacologic treatment for ACS according to the
      applied guidelines offered by the facility. In addition, patients in the intervention group
      will receive Pentoxifylline tablets 400mg orally three times daily.

      Patient follow-up will be scheduled every 2 weeks for each patient to check the tolerability,
      the development of side effects, any medication change and medication adherence. Physical
      examination at each visit will be done by physician in attendance for all patients in both
      groups.

      A blood sample will be taken at baseline and at the end of the study after 2 months. for
      measurement of basic laboratory parameters (Complete Blood Count, Liver Function Tests,
      Kidney Function Tests ,..etc), the level of Soluble Vascular Cell Adhesion Molecule-1
      (sVCAM-1) as a marker for endothelial dysfunction, the level of Malondialdehyde (MDA) as a
      marker for oxidative stress.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Level of Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1) as a marker for endothelial dysfunction</measure>
    <time_frame>Two months</time_frame>
    <description>will be measured at baseline and after 2 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of Malondialdehyde (MDA) as a marker for oxidative stress</measure>
    <time_frame>Two months</time_frame>
    <description>will be measured at baseline and after 2 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of side effects and Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>Two Months</time_frame>
    <description>recorded rate of occurrence in both groups at the end of the study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pentoxifylline tablets 400mg three times daily for 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control Group receiving placebo tablets three times daily for 2 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline</intervention_name>
    <description>Pentoxifylline tablets 400mg three times daily for 2 months</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18-80 years old.

          -  Recent ACS diagnosed-patients within the past 2 weeks.

        Exclusion Criteria:

          -  Known allergy to pentoxifylline

          -  Heart failure New York Heart Association (NYHA) class III or IV

          -  Severe Left Ventricular Dysfunction (left ventricular ejection fraction &lt;30%)

          -  High Serum creatinine level â‰¥ 2 mg/dl

          -  Liver disease (baseline alanine transaminase &gt;2.5 times the upper limit of normal)

          -  Active bleeding or bleeding diathesis

          -  Major surgery or trauma within 1 month

          -  Recent cerebral and/or retinal hemorrhage within 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asmaa Saeed, Bachelor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Teaching Assistant at the Faculty of Pharmacy, Ain Shams University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Asmaa Saeed, Bachelor</last_name>
    <phone>01004390648</phone>
    <phone_ext>02</phone_ext>
    <email>Asmaa.Mohamed2@pharma.asu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marwa Adel, PhD</last_name>
    <phone>01006383120</phone>
    <phone_ext>02</phone_ext>
    <email>dr.marwa.adel2016@gmail.com</email>
  </overall_contact_backup>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 26, 2020</study_first_submitted>
  <study_first_submitted_qc>April 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Asmaa Saeed Mohamed Monir</investigator_full_name>
    <investigator_title>Teaching Assistant</investigator_title>
  </responsible_party>
  <keyword>Acute Coronary Syndrome</keyword>
  <keyword>Pentoxifylline</keyword>
  <keyword>Endothelial Dysfunction</keyword>
  <keyword>Oxidative Stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

